Clinical trial Recruiting at 1 site Observational Ages 18 to 50 Women only

Serum S100B and BDNF levels in women with fibromyalgia

Official title: The Relationship Between Serum S100B and Brain-Derived Neurotrophic Factor (BDNF) Levels and Central Sensitization and Sleep Quality in Patients With Fibromyalgia

Run by Kanuni Sultan Suleyman Training and Research Hospital · NCT07358754 · Data updated 2026-11-12

This project tests whether blood levels of S100B and BDNF differ in women 18–50 with fibromyalgia compared with healthy women and whether those levels relate to central sensitization and sleep quality.

More Fibromyalgia trials

Quick facts

Study typeObservational
Ages18 Years to 50 Years
SexWomen only
Enrollment60 (estimated)
SponsorKanuni Sultan Suleyman Training and Research Hospital
Academic / other
Locations1 site (Istanbul)
StatusRecruiting
StartedFebruary 1, 2026
Main results expectedApril 30, 2026
Study endsApril 30, 2026
Registry record updatedApril 15, 2026
Trial IDNCT07358754 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Women aged 18–50 with a diagnosis of fibromyalgia per 2016 ACR criteria, symptoms for at least three months, who can complete questionnaires and provide informed consent.

Probably not a fit

Men, people outside the 18–50 age range, individuals without fibromyalgia, or patients seeking immediate therapy changes are unlikely to receive direct benefit from this observational biomarker study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This cross-sectional observational study compares serum S100B and BDNF in women diagnosed with fibromyalgia (2016 ACR criteria) and age- and sex-matched healthy controls. Participants will complete questionnaires on symptoms, central sensitization, and sleep, and provide a single blood sample for biomarker measurement. Analyses will compare biomarker levels between groups and test associations between those levels and measures of central sensitization and sleep quality. The study is designed to clarify biomarker patterns rather than to alter clinical care.

Why it matters

Potential benefit: If successful, the findings could identify blood markers that help explain fibromyalgia symptoms and inform future diagnostic or treatment research.

How similar studies have gone: Previous studies have reported altered BDNF and S100B in chronic pain and fibromyalgia, but results have been inconsistent and not yet definitive.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Female participants aged between 18 and 50 years

Diagnosis of fibromyalgia according to 2016 American College of Rheumatology (ACR) criteria

Symptoms present for at least 3 months

Ability to understand and complete study questionnaires

Provision of written informed consent

For healthy controls:

No diagnosis of fibromyalgia or chronic widespread pain

No known systemic disease

Exclusion Criteria:

\-

Where it's running

  • Kanuni Sultan Süleyman Training and Research Hospital
    Istanbul, Turkey (Türkiye)
    Recruiting

Study contacts

  • Principal investigator: Zeynep Karakuzu Güngör, M.D — Kanuni Sultan Süleyman Training and Research Hospital
  • Study coordinator: Zeynep Karakuzu Güngör, M.D
  • Email: zeynepkarakuzu@hotmail.com.tr
  • Phone: 905077750375

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.